Litigation Details for ACADIA Pharmaceuticals Inc. v. MSN Laboratories Private Limited (D. Del. 2022)

ACADIA Pharmaceuticals Inc. v. MSN Laboratories Private Limited (D. Del. 2022)

Docket		Date Filed	2022-10-21
Court	District Court, D. Delaware	Date Terminated
Cause	35:271 Patent Infringement	Assigned To	Gregory B. Williams
Jury Demand	None	Referred To
Patents	11,452,721
Link to Docket	External link to docket

Details for ACADIA Pharmaceuticals Inc. v. MSN Laboratories Private Limited (D. Del. 2022)

Date Filed	Document No.	Description	Snippet	Link To Document
2022-10-21				External link to document

Litigation summary and analysis for: ACADIA Pharmaceuticals Inc. v. MSN Laboratories Private Limited (D. Del. 2022)

Last updated: May 3, 2026

ACADIA Pharmaceuticals Inc. v. MSN Laboratories Private Limited (1:22-cv-01388): Litigation Summary and Patent-Position Analysis

What is the case and where does it sit in the IP timeline?

ACADIA Pharmaceuticals Inc. v. MSN Laboratories Private Limited is a U.S. federal patent litigation filed in the U.S. District Court for the District of Delaware under case number 1:22-cv-01388. The case targets MSN Laboratories’ efforts to market a generic version of an ACADIA-branded product that is protected by one or more patents listed in the Orange Book and Orange Book-linked to the brand sponsor’s FDA-approved product(s).

The caption and docket number indicate a Hatch-Waxman framework (ANDA-related), where ACADIA typically asserts infringement of one or more listed patents, and the defendant seeks FDA approval for a generic before patent expiry. The litigation therefore functions as a mechanism to resolve the “patent wall” around the Orange Book-listed IP.

Who are the parties and what is each side’s litigation posture?

Party	Role	Litigation position (typical in this posture)
ACADIA Pharmaceuticals Inc.	Brand/patent owner and NDA holder (or sponsor)	Asserts that MSN’s ANDA product infringes one or more Orange Book patents and seeks injunctive and monetary relief consistent with Hatch-Waxman remedies.
MSN Laboratories Private Limited	Generic ANDA applicant (defendant)	Challenges ACADIA’s asserted patents via non-infringement and/or invalidity defenses and seeks FDA approval entry consistent with the ANDA carve-outs.

What patents and claims are at issue?

No patent numbers, asserted claim sets, or specific infringement allegations are included in the information provided. Under patent litigation practice, a complete infringement analysis depends on (1) the asserted patent family and claims, (2) the ANDA product description and Paragraph IV (or other) certification particulars, and (3) the claim construction record. Those elements are not available in the prompt, so a claim-by-claim infringement or validity analysis cannot be produced accurately.

What relief is ACADIA seeking and what does MSN need to achieve?

In Hatch-Waxman cases, brand plaintiffs typically seek:

• Permanent injunction (or preliminary relief, if warranted) to bar FDA approval effective before the asserted patents expire or are held invalid/not infringed
• Damages under the statutory framework tied to patent infringement triggered by ANDA notice and FDA approval timing

Defendants typically need to obtain:

• A judgment of non-infringement and/or invalidity for the asserted claims, which then enables a pathway to FDA approval without being blocked by the asserted Orange Book patents
• Potential narrowing outcomes (for example, claim construction outcomes) that reduce infringement exposure

Because the prompt does not provide the procedural posture, claim construction rulings, or the asserted patent list, the relief actually pleaded in the docket cannot be enumerated here.

---

Litigation mechanics: what this case likely hinges on (and what must be proven)

What does ACADIA generally have to show in this type of case?

Issue	ACADIA proof focus
Infringement	The ANDA product meets each limitation of the asserted claims as construed by the court.
Validity	ACADIA must defend against invalidity arguments (anticipation, obviousness, enablement, written description, indefiniteness, claim scope).
Notice and procedural prerequisites	The case rests on the statutory notice and certification pathway. Those details drive whether claims are properly asserted.

What does MSN generally have to show?

Issue	MSN proof focus
Non-infringement	The ANDA product does not fall within one or more construed claim elements (often driven by formulation, release profile, manufacturing, or dosage form features).
Invalidity	Prior art or claim-defect grounds defeat one or more asserted claims.
Claim construction	Getting unfavorable constructions reversed or narrowed is often the highest leverage step.

---

Patent-position analysis framework (how investors and R&D teams should interpret outcomes)

Even without claim and patent specifics in the prompt, litigation outcomes map to a predictable decision tree:

1) If the court adopts ACADIA’s claim construction

• MSN’s infringement case generally tightens because claim elements become more concrete.
• The case often moves toward a settlement posture if core claim limitations appear to be met by the ANDA product formulation or method steps.

2) If the court construes claims narrowly

• ACADIA’s infringement case depends on the ANDA product matching the narrow construction.
• Defendants often leverage narrower interpretations to argue design-around or simple non-infringement.

3) If key claims survive invalidity challenges

• Stronger odds that ACADIA obtains an injunction or other substantial settlement terms.
• Potential impacts include supply entry timing, pricing, and exclusivity economics.

4) If asserted claims are found invalid

• Generic entry becomes significantly easier, subject to remaining un-adjudicated patents in the same Orange Book basket.
• Investors should then evaluate whether ACADIA has additional families or later-expiring secondary patents.

---

What to watch in the docket (decision-critical events)

The prompt does not include the docket record (orders, claim construction briefs, Markman decisions, summary judgment rulings, or trial schedules). In ACADIA-style Hatch-Waxman practice, the highest-impact docket markers typically are:

1. Early case management and briefing schedules
2. Claim construction (Markman) decision
3. Summary judgment orders on infringement and/or invalidity
4. Daubert rulings (expert admissibility)
5. Settlement or dismissal events (partial or full)

Absent the docket text, this analysis cannot anchor to specific dates or rulings.

---

Business and R&D implications for ACADIA

If ACADIA wins

• Generic entry is delayed for the life of the asserted patents or until appeal resolution.
• ACADIA’s downstream planning (commercial forecasting, launch strategy for next-generation formulations, and patent prosecution resource allocation) benefits from a predictable exclusivity runway.

If MSN wins

• Court invalidity and/or non-infringement increases the probability of earlier generic market entry.
• ACADIA would likely shift emphasis toward remaining unasserted or un-adjudicated patents, patent estate durability, and product lifecycle management (including reformulations and new indications, where supported by its patent portfolio).

---

Case-specific litigation analysis (constraints)

The prompt provides only the case name and docket number: ACADIA Pharmaceuticals Inc. v. MSN Laboratories Private Limited | 1:22-cv-01388. It does not provide:

• asserted patent numbers and expiration dates
• ANDA product details relevant to claim charting
• infringement allegations (Paragraph IV versus other certifications)
• claim construction outcomes
• dispositive rulings or trial outcomes
• settlement terms or dismissal basis

Because those are necessary to produce a complete and accurate litigation summary and patent-position analysis, no claim-specific legal conclusions can be stated.

---

Key Takeaways

• The case is a Delaware federal Hatch-Waxman-style patent litigation involving ACADIA as the brand/patent owner and MSN Laboratories as the generic defendant under 1:22-cv-01388.
• A complete patent-position analysis requires the asserted patent list, claim constructions, and the ANDA product allegations, which are not included in the provided information.
• The litigation outcome in this category is driven by claim construction, infringement mapping to the ANDA product, and invalidity strength against prior art.
• Investor and R&D decisions should hinge on Markman and any summary judgment orders, which determine whether ACADIA retains injunction leverage.

---

FAQs

1) What court and case number apply to this matter?

It is filed in U.S. District Court for the District of Delaware as case number 1:22-cv-01388.

2) Is this an ANDA-related patent dispute?

The case caption and docket placement indicate a Hatch-Waxman framework typical of Orange Book-linked patent litigation.

3) What typically determines infringement in these cases?

Whether the ANDA product meets each asserted claim limitation as construed by the court, usually based on the ANDA product description and expert claim charts.

4) What typically determines validity?

Whether the asserted claims are defeated by anticipation/obviousness based on prior art and by statutory claim-defect challenges (depending on what is pleaded and supported by expert testimony).

5) What docket events matter most?

Claim construction (Markman) and any summary judgment decisions on infringement and/or invalidity are typically the highest-impact milestones.

---

References (APA)

1. ACADIA Pharmaceuticals Inc. v. MSN Laboratories Private Limited, No. 1:22-cv-01388 (D. Del.).